AgomAb Therapeutics Completes Euros 21m Series A Financing
GHENT, Belgium--(BUSINESS WIRE)--Apr 3, 2019--AgomAb Therapeutics N.V. ('AgomAb'), a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration…
GHENT, Belgium--(BUSINESS WIRE)--Apr 3, 2019--AgomAb Therapeutics N.V. ('AgomAb'), a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration…